ANI Pharma (ANIP) Misses Q2 EPS by 21c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance
August 7, 2018 8:30 AM EDTBAUDETTE, Minn., Aug. 7, 2018 /PRNewswire/ --Â
For the second quarter 2018:
Net revenues of $47.3 million, an increase of 6% as compared to the same period in 2017Â GAAP net income of $2.8 million and diluted GAAP earnings per share of $0.23 Adjusted non-GAAP EBITDA of $19.0 million Adjusted non-GAAP diluted earnings per share of $1.13ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported its financial results for the three and six months ended June 30, 2018 and updated its 2018 financial guidance. The Company... More
